Indexed by:期刊论文

First Author:Liu, Yubo

Correspondence Author:Zhang, ZC (reprint author), Dalian Univ Technol, Sch Chem, State Key Lab Fine Chem, Dalian, Peoples R China.

Co-author:Xie, Mingzhou,Song, Ting,Sheng, Hongkun,Yu, Xiaoyan,Zhang, Zhichao

Date of Publication:2015-03-01

Journal:PIGMENT CELL & MELANOMA RESEARCH

Included Journals:SCIE、PubMed、Scopus

Volume:28

Issue:2

Page Number:161-170

ISSN No.:1755-1471

Key Words:melanoma; Mcl-1 phosphorylation; BH3 mimetics; Bcl-2 family; mitogen-activated protein kinase pathway

Abstract:The Bcl-2 family modulates sensitivity to chemotherapy in many cancers, including melanoma, in which the RAS/BRAF/MEK/ERK pathway is constitutively activated. Mcl-1, a major anti-apoptotic protein in the Bcl-2 family, is extensively expressed in melanoma and contributes to melanoma's well-documented chemoresistance. Here, we provide the first evidence that Mcl-1 phosphorylation at T163 by ERK1/2 and JNK is associated with the resistance of melanoma cell lines to the existing BH3 mimetics gossypol, S1 and ABT-737, and a novel anti-apoptotic mechanism of phosphorylated Mcl-1 (pMcl-1) is revealed. pMcl-1 antagonized the known BH3 mimetics by sequestering pro-apoptotic proteins that were released from Bcl-2/Mcl-1. Furthermore, an anthraquinone BH3 mimetic, compound 6, was identified to be the first small molecule to that induces endogenous apoptosis in melanoma cells by directly binding Bcl-2, Mcl-1, and pMcl-1 and disrupting the heterodimers of these proteins. Although compound 6 induced upregulation of the pro-apoptotic protein Noxa, its apoptotic induction was independent of Noxa. These data reveal the promising therapeutic potential of targeting pMcl-1 to treat melanoma. Compound 6 is therefore a potent drug that targets pMcl-1 in melanoma.